Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RG1192
- Development stage
- Preclinical
- Lead developer
- OTR3
- Administration
- Intraperitoneal
01
Overview
RG1192 (also known as OTR4120 or RGD120) is a research-stage glycosaminoglycan (GAG) mimetic belonging to the ReGeneraTing Agent (RGTA) family. Developed by the French biotech OTR3, it is a chemically modified dextran polymer substituted with carboxymethyl, sulfate, and benzylamide groups. Structurally designed to mimic heparan sulfates, RG1192 stabilizes and potentiates heparin-binding growth factors (HBGFs) such as fibroblast growth factor 2 (FGF-2) and hepatocyte growth factor (HGF) within the extracellular matrix. Additionally, it acts as a potent inhibitor of Cathepsin G. Preclinical studies have explored its potential in tissue repair and regeneration, including skeletal muscle, peripheral nerves, skin wounds, and intestinal fibrosis associated with Crohn's disease.
- Brand names
- OTR4120OTR-4120OTR 4120Cacicol
- Other names
- RGTAReGeneraTing Agent
02
Targets
FGF2HGF (Hepatocyte growth factor)CTSG (Cathepsin G)
Beyond the preview
Go deeper on RG1192.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RG1192.